Intensive  ||| S:0 E:10 ||| JJ
rTMS  ||| S:10 E:15 ||| JJ
applications  ||| S:15 E:28 ||| NNS
in  ||| S:28 E:31 ||| IN
difficult  ||| S:31 E:41 ||| JJ
to  ||| S:41 E:44 ||| TO
treat  ||| S:44 E:50 ||| VB
psychiatric  ||| S:50 E:62 ||| JJ
patients ||| S:62 E:70 ||| NNS
:  ||| S:70 E:72 ||| :
some  ||| S:72 E:77 ||| DT
cases  ||| S:77 E:83 ||| NNS
Despite  ||| S:83 E:91 ||| IN
adherence  ||| S:91 E:101 ||| VBG
to  ||| S:101 E:104 ||| TO
treatment  ||| S:104 E:114 ||| NN
guidelines ||| S:114 E:124 ||| NNS
,  ||| S:124 E:126 ||| ,
some  ||| S:126 E:131 ||| DT
patients  ||| S:131 E:140 ||| NNS
are  ||| S:140 E:144 ||| VBP
resistant  ||| S:144 E:154 ||| VBN
to  ||| S:154 E:157 ||| TO
several  ||| S:157 E:165 ||| JJ
psychopharmacological  ||| S:165 E:187 ||| JJ
interventions ||| S:187 E:200 ||| NNS
.  ||| S:200 E:202 ||| .
Guidelines  ||| S:202 E:213 ||| NNS
to  ||| S:213 E:216 ||| TO
overcome  ||| S:216 E:225 ||| VB
treatment  ||| S:225 E:235 ||| NN
resistance  ||| S:235 E:246 ||| NN
are  ||| S:246 E:250 ||| VBP
scarce  ||| S:250 E:257 ||| JJ
and  ||| S:257 E:261 ||| CC
new  ||| S:261 E:265 ||| JJ
treatment  ||| S:265 E:275 ||| NN
modalities  ||| S:275 E:286 ||| NNS
are  ||| S:286 E:290 ||| VBP
needed ||| S:290 E:296 ||| VBN
.  ||| S:296 E:298 ||| .
When  ||| S:298 E:303 ||| WRB
confronted  ||| S:303 E:314 ||| VBN
with  ||| S:314 E:319 ||| IN
psychopharmacological  ||| S:319 E:341 ||| JJ
failure ||| S:341 E:348 ||| NN
,  ||| S:348 E:350 ||| ,
repetitive  ||| S:350 E:361 ||| FW
transcranial  ||| S:361 E:374 ||| FW
magnetic  ||| S:374 E:383 ||| FW
stimulation  ||| S:383 E:395 ||| FW
( ||| S:395 E:396 ||| -LRB-
rTMS ||| S:396 E:400 ||| NNP
)  ||| S:400 E:402 ||| -RRB-
therapy  ||| S:402 E:410 ||| NN
can  ||| S:410 E:414 ||| MD
be  ||| S:414 E:417 ||| VB
considered ||| S:417 E:427 ||| VBN
.  ||| S:427 E:429 ||| .
In  ||| S:429 E:432 ||| IN
these  ||| S:432 E:438 ||| DT
case  ||| S:438 E:443 ||| NN
series  ||| S:443 E:450 ||| NN
a  ||| S:450 E:452 ||| DT
combative  ||| S:452 E:462 ||| JJ
high  ||| S:462 E:467 ||| JJ
frequency  ||| S:467 E:477 ||| NN
( ||| S:477 E:478 ||| -LRB-
HF ||| S:478 E:480 ||| NNP
) ||| S:480 E:481 ||| -RRB-
-rTMS  ||| S:481 E:487 ||| JJ
protocol  ||| S:487 E:496 ||| NN
with  ||| S:496 E:501 ||| IN
frequent  ||| S:501 E:510 ||| JJ
stimulations  ||| S:510 E:523 ||| NN
at  ||| S:523 E:526 ||| IN
suprathreshold  ||| S:526 E:541 ||| JJ
intensity  ||| S:541 E:551 ||| NN
was  ||| S:551 E:555 ||| VBD
applied  ||| S:555 E:563 ||| VBN
for  ||| S:563 E:567 ||| IN
treatment-resistant  ||| S:567 E:587 ||| JJ
depression  ||| S:587 E:598 ||| NN
( ||| S:598 E:599 ||| -LRB-
TRD ||| S:599 E:602 ||| NNP
) ||| S:602 E:603 ||| -RRB-
,  ||| S:603 E:605 ||| ,
schizoaffective-  ||| S:605 E:622 ||| JJ
and  ||| S:622 E:626 ||| CC
bipolar  ||| S:626 E:634 ||| JJ
I  ||| S:634 E:636 ||| NN
disorder ||| S:636 E:644 ||| NN
,  ||| S:644 E:646 ||| ,
mixed  ||| S:646 E:652 ||| JJ
episode ||| S:652 E:659 ||| NN
.  ||| S:659 E:661 ||| .
Besides  ||| S:661 E:669 ||| IN
effectiveness ||| S:669 E:682 ||| NN
,  ||| S:682 E:684 ||| ,
tolerability  ||| S:684 E:697 ||| NN
was  ||| S:697 E:701 ||| VBD
closely  ||| S:701 E:709 ||| RB
monitored ||| S:709 E:718 ||| VBN
.  ||| S:718 E:720 ||| .
All  ||| S:720 E:724 ||| DT
three  ||| S:724 E:730 ||| CD
patients ||| S:730 E:738 ||| NNS
,  ||| S:738 E:740 ||| ,
suffering  ||| S:740 E:750 ||| VBG
from  ||| S:750 E:755 ||| IN
different  ||| S:755 E:765 ||| JJ
psychiatric  ||| S:765 E:777 ||| JJ
conditions  ||| S:777 E:788 ||| NNS
were  ||| S:788 E:793 ||| VBD
experiencing  ||| S:793 E:806 ||| VBG
limited  ||| S:806 E:814 ||| VBN
to  ||| S:814 E:817 ||| TO
excellent  ||| S:817 E:827 ||| JJ
clinical  ||| S:827 E:836 ||| JJ
improvement  ||| S:836 E:848 ||| NN
without  ||| S:848 E:856 ||| IN
serious  ||| S:856 E:864 ||| JJ
side  ||| S:864 E:869 ||| NN
effect  ||| S:869 E:876 ||| NN
or  ||| S:876 E:879 ||| CC
adverse  ||| S:879 E:887 ||| JJ
events ||| S:887 E:893 ||| NNS
.  ||| S:893 E:895 ||| .
These  ||| S:895 E:901 ||| DT
very  ||| S:901 E:906 ||| RB
preliminary  ||| S:906 E:918 ||| JJ
results  ||| S:918 E:926 ||| NNS
suggest ||| S:926 E:933 ||| VBP
,  ||| S:933 E:935 ||| ,
along  ||| S:935 E:941 ||| RB
with  ||| S:941 E:946 ||| IN
research  ||| S:946 E:955 ||| NN
using  ||| S:955 E:961 ||| VBG
comparable  ||| S:961 E:972 ||| JJ
intensive  ||| S:972 E:982 ||| JJ
stimulation  ||| S:982 E:994 ||| NN
parameters  ||| S:994 E:1005 ||| NNS
for  ||| S:1005 E:1009 ||| IN
treatment-resistant  ||| S:1009 E:1029 ||| JJ
depression ||| S:1029 E:1039 ||| NN
,  ||| S:1039 E:1041 ||| ,
that  ||| S:1041 E:1046 ||| WDT
' ||| S:1046 E:1047 ||| POS
aggressively ||| S:1047 E:1059 ||| NN
'  ||| S:1059 E:1061 ||| POS
targeting  ||| S:1061 E:1071 ||| VBG
the  ||| S:1071 E:1075 ||| DT
left  ||| S:1075 E:1080 ||| JJ
DLPFC  ||| S:1080 E:1086 ||| NNP
is  ||| S:1086 E:1089 ||| VBZ
well  ||| S:1089 E:1094 ||| RB
tolerated  ||| S:1094 E:1104 ||| JJ
and  ||| S:1104 E:1108 ||| CC
safe ||| S:1108 E:1112 ||| JJ
.  ||| S:1112 E:1114 ||| .
Our  ||| S:1114 E:1118 ||| PRP$
clinical  ||| S:1118 E:1127 ||| JJ
results  ||| S:1127 E:1135 ||| NNS
suggest  ||| S:1135 E:1143 ||| VBP
a  ||| S:1143 E:1145 ||| DT
possible  ||| S:1145 E:1154 ||| JJ
beneficial  ||| S:1154 E:1165 ||| JJ
treatment  ||| S:1165 E:1175 ||| NN
strategy  ||| S:1175 E:1184 ||| NN
of  ||| S:1184 E:1187 ||| IN
HF-rTMS  ||| S:1187 E:1195 ||| JJ
protocols  ||| S:1195 E:1205 ||| NNS
following  ||| S:1205 E:1215 ||| VBG
unsuccessful ||| S:1215 E:1227 ||| JJ
.  ||| S:1227 E:1229 ||| .
Larger  ||| S:1229 E:1236 ||| JJR
sham-controlled  ||| S:1236 E:1252 ||| JJ
studies  ||| S:1252 E:1260 ||| NNS
are  ||| S:1260 E:1264 ||| VBP
needed  ||| S:1264 E:1271 ||| VBN
to  ||| S:1271 E:1274 ||| TO
substantiate  ||| S:1274 E:1287 ||| VB
our  ||| S:1287 E:1291 ||| PRP$
results ||| S:1291 E:1298 ||| NNS
.  ||| S:1298 E:1300 ||| .
